Veracyte, Inc. (NASDAQ:VCYT) is expected to report third quarter earnings results, after market close, on Monday 2nd November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.21 per share.
Looking ahead, the full year loss are expected at $ 0.83 per share on the revenues of $ 105.02 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 138.00 million ~ $ 142.00 million
Click Here For More Historical Outlooks Of Veracyte, Inc.
Previous Quarter Performance
Veracyte, Inc. came out with loss for the second quarter of $ 0.22 per share, from the revenue of $ 20.70 million. The quarterly revenues dropped 31.32 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.24 per share from $ 20.60 million in revenue. The bottom line results beat street analysts by $ 0.02 or 8.33 percent, at the same time, top line results outshined analysts by $ 0.10 million or 0.49 percent.
Stock Performance
On Friday, shares of Veracyte, Inc. has traded high as $ 37.00 and has cracked $ 33.86 on the downward trend, reaching $ 34.66 with volume of 487.10 thousand shares.
According to the previous trading day, closing price of $ 34.66, representing a 164.82 % increase from the 52 week low of $ 13.90 and a 17.54 % decrease over the 52 week high of $ 44.64.
The company has a market capital of $ 1.99 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 9th September 2020, initiated by Morgan Stanley at Underweight rating, with $ 35.00 target price.
Conference Call
Veracyte, Inc. will be hosting a conference call at 4:30 PM eastern time on 2nd November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.veracyte.com
Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis.
